Clinical Trial: A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07190833) titled 'A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)' on Sept. 17.

Brief Summary: This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Treatment-Refractory Solid Tumors

Intervention: DRUG: OTS-412

1x10E8 pfu, once, 1 cycle, IT

DRUG: Hydroxyurea (HU)

15 mg/kg/day, 14 days, 1 cycle, PO

DRUG: Hydroxyurea (HU)...